ClinConnect ClinConnect Logo
Search / Trial NCT05178498

Impact of Dietary Inflammatory Potential on Breast Cancer Risk

Launched by OHIO STATE UNIVERSITY COMPREHENSIVE CANCER CENTER · Dec 16, 2021

Trial Information

Current as of July 09, 2025

Recruiting

Keywords

ClinConnect Summary

This clinical trial is looking at how the types of foods we eat might affect the risk of developing breast cancer. Researchers want to understand if certain diets, which can cause inflammation in the body, may influence the chances of getting breast-related conditions like atypical ductal hyperplasia or lobular carcinoma in situ. The goal is to find ways to identify people at higher risk and to improve strategies for preventing breast cancer by helping doctors make better recommendations about diet.

To participate in this study, you need to be at least 18 years old and have been seen at a high-risk clinic for breast cancer. This includes individuals with a family history of breast cancer or those who have had specific breast-related conditions. You should also be able to read and understand English and provide consent to let researchers follow your medical records during the study. If you join, you can expect to share information about your diet and health, which may help improve future breast cancer prevention efforts.

Gender

ALL

Eligibility criteria

  • Inclusion Criteria:
  • Age \>= 18 years
  • Established in the high risk clinic at OSUCCC- James (includes patients with family history of breast cancer \[BC\], known genetic predisposition, personal history of known atypia/breast lobular carcinoma in situ \[LCIS\], or prior chest wall radiation)
  • Patients at high risk for BC established in the surgical oncology clinic at Stefanie Spielman Comprehensive Breast Center (SSCBC), with one of the following diagnoses: Atypical ductal hyperplasia (ADH), atypical lobular hyperplasia (ALH), lobular carcinoma in situ (LCIS), sclerosing adenosis (SA), or radial scars (RS)
  • Able to read and understand English
  • Able to provide informed consent
  • Must consent to continued follow-up of medical records during the study period
  • Exclusion Criteria:
  • Prisoners
  • Not able to speak and understand English
  • Known personal history of ductal carcinoma in situ (DCIS) or Invasive BC

About Ohio State University Comprehensive Cancer Center

The Ohio State University Comprehensive Cancer Center (OSUCCC) is a leading institution dedicated to advancing cancer research, treatment, and education. As a National Cancer Institute-designated comprehensive cancer center, OSUCCC integrates cutting-edge research with clinical practice to develop innovative therapies and improve patient outcomes. With a collaborative approach that unites scientists and clinicians, OSUCCC focuses on personalized medicine, cancer prevention, and community outreach, striving to enhance the understanding of cancer biology and provide hope to patients through groundbreaking clinical trials and comprehensive care programs.

Locations

Columbus, Ohio, United States

Patients applied

0 patients applied

Trial Officials

Sagar D Sardesai, MSPH, PhD

Principal Investigator

Ohio State University Comprehensive Cancer Center

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported

Similar Trials